SYFabd907ca444943c0824d7b9410f59701Registry ID: 2024-515109-24-00|RecruitingPhase 3
Loading search results
interventional
N/A
1 country
1
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 6, 2024
Actual (reported)Cancer progression (based on radiological, biochemical or clinical evaluation) and mortality (evaluated by time from starting 1. line cancer treatment to death)
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Lipistad 40 mg kalvopäällysteiset tabletit
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
FILM-COATED TABLET
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Lipistad 40 mg kalvopäällysteiset tabletit
Named ingredient: Atorvastatin
View registry recordPirkanmaan hyvinvointialue
Tampere, 33520, Finland
Teemu Murtola
First Submitted
August 6, 2024
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to confirm eligibility.